Skip to main content
. 2026 Jul 18;26:1806. doi: 10.1186/s12879-026-14011-0

Table 1.

Comparison of the epidemiological and clinical characteristics of case patients and control patients aged ≤ 1 year, Diyarbakır, 2012–2024

Variable Case patients (N:309)
n (%)a
Control patients (N:927)
n (%)a
p-valueb
Age [median (Q1–Q3)], months 8.6 (7.2–10.3) 7.5 (5.4–9.3) < 0.001
Age group, months

< 0.001

p-trend < 0.001

 0–6 71 (23) 406 (43.8)
 7–9 100 (32.3) 249 (26.9)
 10–12 138 (44.7) 272 (29.3)
Sex 0.97
 Female 136 (44) 409 (44.1)
 Male 173 (56) 518 (55.9)
Migrant status 0.055
 Non-immigrant 302 (97.7) 920 (99.2)
 Immigrant 7 (2.3) 7 (0.8)
Place of residencec  Valid: 75/309 Valid: 218/927 0.03
 Central districts 65 (86.7) 163 (74.8)
 Outlying districts 10 (13.3) 55 (25.2)
Epidemic year < 0.001
 Yes 270 (87.4) 721 (77.8)
 No 39 (12.6) 206 (22.2)
Season < 0.001
 Autumn 12 (3.9) 80 (8.6)
 Winter 33 (10.7) 166 (17.9)
 Spring 125 (40.4) 250 (27)
 Summer 139 (45) 431 (46.5)
Vaccination status 0.001
 Unvaccinated 308 (99.7) 887 (95.7)
 Early dosed 1 (0.3) 40 (4.3)
Clinical symptomsc
 Fever Valid: 281/309 Valid: 785/927 < 0.001
 Yes 259 (92.2) 623 (79.4)
 No 22 (7.8) 162 (20.6)
Upper respiratory symptoms Valid: 278/309 Valid: 780/927 < 0.001
 Yes 238 (85.6) 483 (61.9)
 No 40 (14.4) 297 (38.1)
Lymphadenopathy/arthralgia Valid: 149/309 Valid: 524/927 0.02
 Yes 9 (6) 11 (2.1)
 No 140 (94) 513 (97.9)
Hospitalizationc Valid: 304/309 Valid: 918/927 < 0.001
 Yes 47 (15.5) 36 (3.9)
 No 257 (84.5) 882 (96.1)

aColumn percentages are presented

bP value for comparison between case patients versus control patients. Age compared using the Mann–Whitney U test; all other variables compared using Pearson’s chi-square test, Fisher’s exact test, or the chi-square test for trend

cFor variables with missing data, the number of individuals with available data out of the total number in each group is shown in the case patient and control patient columns. Percentages and p-values were calculated among individuals with available data

dEarly dose: Measles-containing vaccine administered at 9–11 months of age